InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone617-863-5500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions
What is Invivo Therapeutics' stock symbol?
Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."
When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?
Invivo Therapeutics's stock reverse split on the morning of Tuesday, April 17th 2018. The 1-25 reverse split was announced on Monday, April 9th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 16th 2018. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 4 shares after the split.
How were Invivo Therapeutics' earnings last quarter?
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) posted its quarterly earnings data on Tuesday, August, 13th. The biotechnology company reported ($0.34) earnings per share for the quarter. View Invivo Therapeutics' Earnings History.
When is Invivo Therapeutics' next earnings date?
Has Invivo Therapeutics been receiving favorable news coverage?
News headlines about NVIV stock have been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Invivo Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Invivo Therapeutics.
Are investors shorting Invivo Therapeutics?
Invivo Therapeutics saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 17,100 shares, a decline of 54.6% from the August 30th total of 37,700 shares. Based on an average daily volume of 41,700 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.2% of the shares of the stock are sold short. View Invivo Therapeutics' Current Options Chain.
Who are some of Invivo Therapeutics' key competitors?
Some companies that are related to Invivo Therapeutics include Co-Diagnostics (CODX), Restoration Robotics (HAIR), RA Medical Systems (RMED), Atossa Genetics (ATOS), Hancock Jaffe Laboratories (HJLI), Lianluo Smart (LLIT), Titan Medical (TMDI), DarioHealth (DRIO), Obalon Therapeutics (OBLN), Dynatronics (DYNT), Valeritas (VLRX), Avinger (AVGR), Sintx Technologies (SINT), CELLECT BIOTECH/S (APOP) and Cytori Therapeutics (CYTX).
What other stocks do shareholders of Invivo Therapeutics own?
Who are Invivo Therapeutics' key executives?
Invivo Therapeutics' management team includes the folowing people:
- Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)
- Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 70)
- Dr. Joseph Philip Vacanti, Co-Founder (Age 70)
- Mr. Richard C. Christopher, Chief Financial Officer (Age 49)
- Mr. William D'Agostino PE, Sr. VP of Operations
How do I buy shares of Invivo Therapeutics?
Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Invivo Therapeutics' stock price today?
One share of NVIV stock can currently be purchased for approximately $0.49.
How big of a company is Invivo Therapeutics?
Invivo Therapeutics has a market capitalization of $4.56 million. The biotechnology company earns $-23,420,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Invivo Therapeutics employs 6 workers across the globe.View Additional Information About Invivo Therapeutics.
What is Invivo Therapeutics' official website?
How can I contact Invivo Therapeutics?
Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]
MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
